Evaluating piperacillin-tazobactam effectiveness in obese patients
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity: an Open Randomized Controlled Feasibility Study
This study is testing if a different way of giving a common antibiotic can work better for hospitalized adults with obesity.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CR-CSSS Champlain-Charles-Le Moyne Academic / other |
| Locations | 1 site (Greenfield Park, Quebec) |
| Trial ID | NCT06690905 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of piperacillin-tazobactam in patients with obesity by comparing the pharmacodynamic parameters achieved through prolonged intermittent infusion versus standard infusion. It is an open randomized controlled trial focusing on hospitalized adults with a body mass index of 30 kg/m² or higher. The primary goal is to determine the proportion of patients achieving a favorable pharmacodynamic target after 24 hours of treatment. The study is conducted at Hôpital Charles-Le Moyne in Quebec.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with obesity who are hospitalized and have recently started piperacillin-tazobactam.
Not a fit: Patients with documented allergies to beta-lactams, those undergoing renal replacement therapy, or those with a history of seizures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could optimize antibiotic treatment for obese patients, potentially improving infection outcomes.
How similar studies have performed: While this approach is novel in the context of obesity, similar studies have shown the importance of pharmacodynamics in optimizing antibiotic therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (18 years and older) * Patients hospitalized at Hôpital Charles-Le Moyne * Obesity (as defined by a body mass index of ≥ 30 kg/m\^2) * Piperacillin-tazobactam prescription initiated within last 24 hours * Planned duration of piperacillin-tazobactam of 24 hours or more Exclusion Criteria: * Documented allergy to beta-lactams of the penicillin class * Patients with renal replacement therapy (hemodialysis, peritoneal dialysis, continuous venovenous hemodiafiltration) * Pregnancy * History of seizures or epilepsy, active seizures or epilepsy treated with antiepileptic drug therapy * Patients on prolonged intermittent infusion or continuous infusion of piperacillin-tazobactam before randomization
Where this trial is running
Greenfield Park, Quebec
- Hôpital Charles- Le Moyne — Greenfield Park, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Benoît Crevier, PharmD., MSc., BCCCP
- Email: benoit.crevier.cisssmc16@ssss.gouv.qc.ca
- Phone: 1 450-466-5000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.